The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Abstract
BACKGROUND: Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgitation. METHODS: We used data from the United Kingdom General Practice Research Database to identify a population-based cohort comprising 11,417 subjects 40 to 80 years of age who were prescribed antiparkinsonian drugs between 1988 and 2005. We conducted a nested case-control analysis within this cohort in which each patient with newly diagnosed cardiac-valve regurgitation was matched with up to 25 control subjects from the cohort, according to age, sex, and year of entry into the cohort. Incidence-rate ratios for cardiac-valve regurgitation with the use of different dopamine agonists were estimated by conditional logistic-regression analysis. RESULTS: Of 31 case patients with newly diagnosed cardiac-valve regurgitation, 6 were currently exposed to pergolide, 6 were currently exposed to cabergoline, and 19 had not been exposed to any dopamine agonist within the previous year. The rate of cardiac-valve regurgitation was increased with current use of pergolide (incidence-rate ratio, 7.1; 95% confidence interval [CI], 2.3 to 22.3) and cabergoline (incidence-rate ratio, 4.9; 95% CI, 1.5 to 15.6), but not with current use of other dopamine agonists. CONCLUSIONS: In this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ekbom, K. A. (1960) · Neurology · doi:10.1212/wnl.10.9.868 · Cited by 841
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Validity of the General Practice Research Database
Jick, S. S., Kaye, J. A., Vasilakis‐Scaramozza, C., Rodríguez, L. A. G., Ruigómez, A., Meier, C. R., Schlienger, R. G., Black, C., & Jick, H. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.686.32205 · Cited by 584
Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.-A., & Newman-Tancredi, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039867 · Cited by 484
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
Van Camp, G., Flamez, A., Cosyns, B., Weytjens, C., Muyldermans, L., Van Zandijcke, M., De Sutter, J., Santens, P., Decoodt, P., Moerman, C., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15945-x · Cited by 321
Earley, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp021288 · Cited by 309
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Signaling from G-Protein-coupled Receptors to Mitogen-activated Protein (MAP)-Kinase Cascades
Lopez-Ilasaca, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00059-8 · Cited by 272
A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation
Jick, H., Vasilakis, C., Weinrauch, L. A., Meier, C. R., Jick, S. S., & Derby, L. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391102 · Cited by 263
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
Valvular Heart Disease in Patients Taking Pergolide
Pritchett, A. M., Morrison, J. F., Edwards, W. D., Schaff, H. V., Connolly, H. M., & Espinosa, R. E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.12.1280 · Cited by 222
Newman-Tancredi, A., Cussac, D., Quentric, Y., Touzard, M., Verrièle, L., Carpentier, N., & Millan, M. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039883 · Cited by 194
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
Baseman, D., O’Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., & Dewey, R. B. (2004) · Neurology · doi:10.1212/01.wnl.0000129842.49926.07 · Cited by 119
Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
Camp, G. V., Flamez, A., Cosyns, B., Goldstein, J. W., Perdaens, C., & Schoors, D. (2003) · Neurology · doi:10.1212/01.wnl.0000083985.00343.f2 · Cited by 115
Fibrotic Valvular Heart Disease Subsequent to Bromocriptine Treatment
Serratrice, J., DISDIER, P., Habib, G., Viallet, F., & Weiller, P. (2002) · Cardiology in Review · doi:10.1097/00045415-200211000-00005 · Cited by 106
Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero, A., Marcos‐Alberca, P., & Fortes, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511033531822 · Cited by 98
Agonism at 5-HT2B receptors is not a class effect of the ergolines
Jähnichen, S., HOROWSKI, R., & Pertz, H. H. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.010 · Cited by 95
Dhawan, V., Medcalf, P., Stegie, F., Jackson, G. S., Basu, S., Luce, P. J., Odin, P., & Chaudhuri, К. R. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0289-1 · Cited by 46
Cited by
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182
Self-citation
Metadata
- Authors
- Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 29-38
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112309011
- Cited by
- 718
- References
- 22
- FWCI
- 57.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.